Martin Früh

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

J. Mazieres, Alexander Drilon, Amélie Lusque et al. · Annals of Oncology · 2019 · 1.3K citations · Full text

Advanced Lung Cancer, Cancer Immunosurveillance, Medicine +12

Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab

Stefan Diem, Sabine Schmid, M. Krapf et al. · Lung Cancer · 2017 · 992 citations

Medicine, Immunology, Pathology +8

Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Martin Früh, Dirk De Ruysscher, Sanjay Popat et al. · Annals of Oncology · 2013 · 608 citations · Full text

Medicine, Cancer Management, Pulmonary Blastoma +6

Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

Anne‐Marie C. Dingemans, Martin Früh, Andrea Ardizzoni et al. · Annals of Oncology · 2021 · 530 citations · Full text

Medicine, Cancer Management, Bronchial Neoplasm +7

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

Myriam Delaunay, J. Cadranel, Amélie Lusque et al. · European Respiratory Journal · 2017 · 416 citations · Full text